PFO Closure for Cryptogenic Stroke
详细信息    查看全文
  • 作者：Sabreena J. Gillow ; Vivien H. Lee
  • 关键词：Patent foramen ovale (PFO) ; Cryptogenic ischemic stroke ; Transcatheter closure ; Surgical closure ; Atrial septal aneurysm (ASA)
  • 刊名：Current Atherosclerosis Reports
  • 出版年：2015
  • 出版时间：August 2015
  • 年：2015
  • 卷：17
  • 期：8
  • 全文大小：319 KB
  • 参考文献：1.Lippman H, Rafferty T. Patent foramen ovale and paradoxical embolization: a historical perspective. Yale J of Biol and Med. 1993;66:11–7.
    2.Mugge A, Daniel WG, Angermann C, Spes C, et al. Atrial septal aneurysm in adult patients. A multicenter study using transthoracic and transesophageal echocardiography. Circulation. 1995;91(11):2785–92.PubMed CrossRef
    3.Hagen PT, Scholz DG, Edwards WD. Incidence and size of patent foramen ovale during the first 10 decades of life: an autopsy study of 965 normal hearts. Mayo Clin Proc. 1984;59(1):17–20.PubMed CrossRef
    4.Homma S, Sacco RL. Patent foramen ovale and stroke. Circulation. 2005;112:1063–107.PubMed CrossRef
    5.Ranoux D, Cohen A, Cabanes L, Amarenco P, et al. Patent foramen ovale: is stroke due to paradoxical embolism? Stroke. 1993;24(1):31–4.PubMed CrossRef
    6.Cormack L, Murchison JT. Paradoxical embolus straddling patent foramen ovale demonstrated by computed tomographic pulmonary angiography. World J Clin Cases. 2013;1(3):108–10.PubMedCentral PubMed CrossRef
    7.Mas J, Arquizan C, Lamy C, Zuber M. Recurrent cerebrovascular events associated with patent foramen ovale, atrial septal aneurysm, or both. N Engl J Med. 2001;345(24):1740–6.PubMed CrossRef
    8.Consoli D, Paciaroni M, Galati F, Aguggia M, et al. Prevalence of patent foramen ovale in ischaemic stroke in Italy: results of SISIFO study. Cerebrovasc Dis. 2015;34(3-4):162–9.CrossRef
    9.Meyer MA. Patent foramen ovale and cryptogenic stroke. N Engl J Med. 2008;358(14):1518.PubMed CrossRef
    10.Kolominsky-Rabas PL, Weber M, Gefeller O, Neundoerfer B, et al. Epidemiology of ischemic stroke subtypes according to TOAST criteria: incidence, recurrence, and long-term survival in ischemic stroke subtypes: a population-based study. Stroke J Cerebral Circ. 2001;32(12):2735–40.CrossRef
    11.Sacco RL, Ellenberg JH, Mohr JP, Tatemichi TK, et al. Infarcts of undetermined cause: the NINCDS Stroke Data Bank. Ann Neurol. 1989;25(4):382–90.PubMed CrossRef
    12.Putaala J, Metso AJ, Metso TM, Konkola N, et al. Analysis of 1008 consecutive patients aged 15 to 49 with first-ever ischemic stroke: the Helsinki young stroke registry. Stroke. 2009;40(4):1195–203.PubMed CrossRef
    13.Lechat P, Mas JL, Lascault G, Loron P, et al. Prevalence of patent foramen ovale in patients with stroke. N Engl J Med. 1988;318(18):1148–52.PubMed CrossRef
    14.Webster MW, Chancellor AM, Smith HJ, Swift DL, et al. Patent foramen ovale in young stroke patients. Lancet. 1988;2(8601):11–2.PubMed CrossRef
    15.Handke M, Harloff A, Olschewski M, Hetzel A, et al. Patent foramen ovale and cryptogenic stroke in older patients. N Engl J Med. 2007;357:2262–8.PubMed CrossRef
    16.Petty GW, Khandheria BK, Meissner I, Whisnant JP, et al. Population-based study of the relationship between patent foramen ovlae and cerebrovascular ischemic events. Mayo Clin Proc. 2006;81(5):602–8.PubMed CrossRef
    17.Meissner I, Khandheria BK, Heit JA, Petty GW, et al. Patent foramen ovale: innocent or guilty? Evidence from a prospective population-based study. J Am Coll Cardiol. 2006;47(2):440–5.PubMed CrossRef
    18.Di Tullio MR, Sacco RL, Sciacca RR, Jin Z, et al. Patent foramen ovale and the risk of ischemic stroke in a multiethnic population. J Am Coll Cardiol. 2007;49(7):797–802.PubMed CrossRef
    19.Almekhlafi MA, Wilton SB, Rabi DM, Ghali WA, et al. Recurrent cerebral ischemia in medically treated patent foramen ovale: a meta-analysis. Neurology. 2009;73:89–97.PubMed CrossRef
    20.Cabenes L, Mas JL, Cohen A, Amarenco P, et al. Atrial septal aneurysm and patent foramen ovale as risk factors for cryptogenic stroke in patients less than 55 years of age. A study using transesophageal echocardiography. Stroke. 1993;24(12):1865–73.CrossRef
    21.Orgera MA, O’Malley PG, Taylor AJ. Secondary prevention of cerebral ischemia in patent foramen ovale: systematic review and meta-analysis. South Med J. 2001;94(7):699–703.PubMed CrossRef
    22.Homma S, Sacco RL, Di Tullio MR, Sciacca RR, et al. Effect of medical treatment in stroke patients with patent foramen ovale: patent foramen ovale in cryptogenic stroke study. Circulation. 2002;105:2625–31.PubMed CrossRef
    23.Mohr JP, Thompson JL, Lazar RM, et al. A comparison of warfarin and aspirin for the prevention of recurrent ischemic stroke. N Engl J Med. 2001;345(20):1444–51.PubMed CrossRef
    24.Cujec B, Mainra R, Johnson DH. Prevention of recurrent cerebral ischemic events in patients with patent foramen ovale and cryptogenic strokes or transient ischemic attacks. Can J Cardiol. 1999;15(1):57–64.PubMed
    25.De Castro S, Cartoni D, Fiorelli M, Rasura M, et al. Morphological and functional characteristics of patent foramen ovale and their embolic implications. Stroke. 2000;31(10):2407–13.PubMed CrossRef
    26.Nedeltchev K, Arnold M, Wahl A, Sturzeneggar M, et al. Outcome of patients with cryptogenic stroke and patent foramen ovale. J Neurol Neurosurg Psychiatry. 2001;72:347–50.CrossRef
    27.Furlan AJ. Patent foramen ovale and stroke: to close or not to close? Cleve Clin J of Med. 2007;74(1):S118–120.CrossRef
    28.Devuyst G, Bogousslavsky J, Ruchat P, Jeanrenaud X. Prognosis after stroke followed by surgical closure of patent foramen ovale: a prospective follow-up study with brain MRI and simultaneous transesophageal and transcranial Doppler ultrasound. Neurology. 1996;47(5):1162–6.PubMed CrossRef
    29.Dearani JA, Ugurlu BS. Surgical patent foramen ovale closure for prevention of paradoxical embolism-related cerebrovascular ischemic events. Circulation. 1999;100(10 suppl):II171–5.PubMed
    30.Bridges ND, Hellenbrand W, Latson L, Filiano J, et al. Transcatheter closure of patent foramen ovale after presumed paradoxical embolism. Circulation. 1999;86(6):1902–8.CrossRef
    31.Khairy P, O’Donnell CP, Landzberg MJ. Transcatheter closure versus medical therapy of patent foramen ovale and presumed paradoxical thromboemboli: a systematic review. Ann Intern Med. 2003;139(9):753–60.PubMed CrossRef
    32.Windecker S, Wahl A, Nedeltchev K, Arnold M, et al. Comparison of medical treatment with percutaneous closure of patent foramen ovale in patients with cryptogenic stroke. J Am Coll Cardiol. 2004;44(4):750–8.PubMed CrossRef
    33.Thanopoulos BV, Dardas PD, Karanasios E, Mezilis N. Transcatheter closure versus medical therapy of patent foramen ovale and cryptogenic stroke. Catheter Cardiovasc Interv. 2006;68(5):741–6.PubMed CrossRef
    34.Casaubon L, McLaughlin P, Webb G, Yeo E, et al. Recurrent stroke/TIA in cryptogenic stroke patients with patent foramen ovale. Can J Neurol Sci. 2007;34(1):74–80.PubMed CrossRef
    35.Harrer JU, Wessels T, Franke A, Lucas S. Stroke recurrence and its prevention in patients with patent foramen ovale. Can J Neurol Sci. 2006;33(1):39–47.PubMed CrossRef
    36.Martin F, Sanchez PL, Doherty E, Colon-Hernandez PJ, et al. Percutaneous transcatheter closure of patent foramen ovale in patients with paradoxical embolism. Circulation. 2002;106(9):1121–6.PubMed CrossRef
    37.Wahl A, Meier B, Haxel B, Nedeltchev K, et al. Prognosis after percutaneous closure of patent foramen ovale for paradoxical embolism. Neurology. 2001;57(7):1330–2.PubMed CrossRef
    38.Windecker S, Wahl A, Chatterjee T, Garachemani A, et al. Percutaneous closure of patent foramen ovale in patients with paradoxical embolism:long-term risk of recurrent thromboembolic events. Circulation. 2000;101(8):893–8.PubMed CrossRef
    39.Wahl A, Krumsdorf U, Meier B, Sievert H, et al. Transcatheter treatment of atrial septal aneurysm associated with patent foramen ovale for prevention of recurrent paradoxical embolism in high-risk patients. J Am Coll Cardiol. 2005;45(3):377–80.PubMed CrossRef
    40.Rudolph V, Augustin J, Hofmann T, Hamm CW, et al. Predictors of recurrent stroke after percutaneous closure of patent foramen ovale. EuroIntervention. 2014;9(12):1418–22.PubMed CrossRef
    41.Schwerzmann M, Salehian O. Hazards of percutaneous closure. Eur J Echocardiogr. 2005;6(6):393–5.PubMed CrossRef
    42.Schoen SP, Boscheri A, Lange SA, Braun MU, et al. Incidence of aortic valve regurgitation and outcome after percutaneous closure of atrial septal defects and patent foramen ovale. Heart. 2008;94(7):844–7.PubMed CrossRef
    43.Kiblawi FM, Sommer RJ, Levchuck SG. Transcatheter closure of patent foramen ovale in older adults. Catheter Cardiovasc Interv. 2006;68(1):136–42.PubMed CrossRef
    44.Alaeddini J, Feghali G, Jenkins S, Ramee S, et al. Frequency of atrial tachyarrhythmias following transcatheter closure of patent foramen ovale. J Invasive Cardiol. 2006;18(8):365–8.PubMed
    45.Slottow TLP, Steinberg DH, Waksman R. Overview of the 2007 food and drug administration circulatory system devices panel meeting on patent foramen ovale closure devices. Circulation. 2007;116:677–82.PubMed CrossRef
    46.Messe SR, Silverman IE, Kizer JR, Homma S, et al. Practice parameter: recurrent stroke with patent foramen ovale and atrial septal aneurysm: report of the quality standards subcommittee of the American Academy of Neurology. Neurology. 2004;62(7):1042–50.PubMed CrossRef
    47.Sacco RL, Adams R, Albers G, Alberts MJ, et al. Guidelines for prevention of stroke in patients with ischemic stroke or transient ischemic attack: a statement for healthcare professionals from the American Heart Association/American Stroke Association Council on Stroke: co-sponsored by the Council on Cardiovascular Radiology and Intervention: the American Academy of Neurology affirms the value of this guideline. Circulation. 2006;113:e409–49.PubMed
    48.••
Furlan AJ, Reisman M, Massaro J, Mauri L, et al. Closure or medical therapy for cryptogenic stroke with patent foramen ovale. N Engl J Med. 2012;366(11):991–9. This is a recently published randomized controlled trial to assess whether closure or medical therapy leads to less recurrence of ischemic strokes. Findings showed no significant improvement in rates of recurrence of stroke or TIA in cases with closure over medical therapy, even when degree of shunting was taken into account.PubMed CrossRef
49.••
Meier B, Kalesan B, Mattle HP, Khattab AA. Percutaneous closure of patent foramen ovale in cryptogenic embolism. N Engl J Med. 2013;368(12):1083–91. This is a recently published randomized controlled trial to assess whether closure or medical therapy leads to less recurrence of ischemic events. Findings showed no significant improvement in rates of recurrence of stroke or TIA, as well as peripheral embolism, in cases with closure over medical therapy.PubMed CrossRef
50.••
Carroll J, Saver JL, Thaler DE, Smalling RW, et al. Closure of patent foramen ovale versus medical therapy after cryptogenic strokes. N Engl J Med. 2013;368(12):1092–100.PubMed CrossRef
51.Chen L, Luo S, Yan L, Zhao W. A systematic review of closure versus medical therapy for preventing recurrent stroke in patients with patent foramen ovale and cryptogenic stroke or transient ischemic attack. J Neurol Sci. 2014;337(1-2):3–7.PubMed CrossRef
52.Pineda AM, Nascimento FO, Yang SC, Kirtane AJ, et al. A meta-analysis of transcatheter closure of patent foramen ovale versus medical therapy for prevention of recurrent thromboembolic events in patients with cryptogenic cerebrovascular events. Catheter Cardiovasc Interv. 2013;82(6):968–75.PubMed CrossRef
53.Khan AR, Bin Abdulhak AA, Sheikh MA, Khan S, et al. Device closure of patent foramen ovale versus medical therapy in cryptogenic stroke. JACC Cardiovasc Interv. 2013;12:1316–23.CrossRef
54.•
Ponnuthurai FA, van Gaal WJ, Burchell A, Mitchell A, et al. Single centre experience with GORE-HELEX Septal Occluder for closure of PFO. Heart Lung Circ. 2009;18(2):140–2. This is an ongoing phase 3 clinical trial evaluating whether closure with the GORE HELEX Septal Occluder/GORE Septal Occluder reduces incidence of recurrent stroke compared with medical therapy alone. The study is still ongoing; however, there is an improved effective closure rate with this device compared to previous trials.PubMed CrossRef
55.••Kernan WN, Ovbiagele B, Black HR, Bravata DM, et al. Guidelines for the prevention of stroke in patients with stroke and transient ischemic attack: a guideline for healthcare professionals from the American Heart Association/American Stroke Association. Stroke. 2014;45(7):2160–236. These are the revised 2014 American Heart Association/American Stroke Association guidelines for secondary stroke prevention.PubMed CrossRef
  • 作者单位：Sabreena J. Gillow (1)
    Vivien H. Lee (1)

    1. Department of Neurological Sciences, Section of Cerebrovascular Disease, Rush University Medical Center, 1725 W. Harrison St #1121, Chicago, IL, 60612, USA
  • 刊物主题：Angiology; Cardiology;
  • 出版者：Springer US
  • ISSN：1534-6242
    • 文摘
    A patent foramen ovale (PFO) is a common finding in the general population and has been theorized to be a mechanism for ischemic stroke primarily due to a deep venous thrombus embolizing through the shunt into the arterial circulation. There has been much debate regarding the association between PFO and stroke, especially in the case of a cryptogenic stroke (i.e., stroke of unknown etiology) in a younger patient without other risk factors. Traditionally, when a PFO is detected, antithrombotic therapy to mitigate risk of a future ischemic event has been the mainstay of treatment. More recently, both surgical and transcatheter closure of a PFO have been widely utilized. However, there are only few randomized controlled trials assessing the efficacy of PFO closure for stroke prevention.

    © 2004-2018 中国地质图书馆版权所有 京ICP备05064691号 京公网安备11010802017129号

    地址：北京市海淀区学院路29号 邮编：100083

    电话：办公室：(+86 10)66554848；文献借阅、咨询服务、科技查新：66554700